It has been hypothesized that visfatin promotes breast cancer survival through the ABL proto-oncogene 1 (c-Abl) activator of the transcription 3 (STAT3) pathway and via upregulation of the mRNA levels of cyclin D1 and cyclin-dependent kinase 2 (CDK2). The gene discussed is CDK2; the disease is breast carcinoma.